Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cognetivity Neurosciences (STU:1UB) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Oct. 2023, Cognetivity Neurosciences has a Sloan Ratio of -975.00%, indicating earnings are more likely to be made up of accruals.
Cognetivity Neurosciences Sloan Ratio % Related Terms
Cognetivity Neurosciences Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1UB vs VEEV, GEHC, HQY: Sloan Ratio % Comparison
For the Health Information Services subindustry, Cognetivity Neurosciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cognetivity Neurosciences Sloan Ratio % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cognetivity Neurosciences's Sloan Ratio % falls into.
Cognetivity Neurosciences Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cognetivity Neurosciences's Sloan Ratio for the fiscal year that ended in Jan. 2023 is calculated as
Cognetivity Neurosciences's Net Income for the trailing twelve months (TTM) ended in Oct. 2023 was -1.773 (Jan. 2023 ) + -1.425 (Apr. 2023 ) + -1.324 (Jul. 2023 ) + -1.407 (Oct. 2023 ) = €-5.93 Mil.
Cognetivity Neurosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Oct. 2023 was -1.16 (Jan. 2023 ) + -1.031 (Apr. 2023 ) + -0.458 (Jul. 2023 ) + 0.012 (Oct. 2023 ) = €-2.64 Mil.
Cognetivity Neurosciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Oct. 2023 was 0.003 (Jan. 2023 ) + -0.003 (Apr. 2023 ) + -0.003 (Jul. 2023 ) + -0.013 (Oct. 2023 ) = €-0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cognetivity Neurosciences (STU:1UB) has a Sloan Ratio % of -975.00% as of Oct. 2023. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cognetivity Neurosciences and its competitors.
Is Cognetivity Neurosciences' Sloan Ratio % too high?
Cognetivity Neurosciences' current Sloan Ratio % is -975.00%.
How does Cognetivity Neurosciences' Sloan Ratio % compare to VEEV and GEHC?
Cognetivity Neurosciences' Sloan Ratio % of -975.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Healthcare Providers & Services company?
A good Sloan Ratio % depends on the Healthcare Providers & Services industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cognetivity Neurosciences and its competitors. Cognetivity Neurosciences's current Sloan Ratio % is -975.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (STU:1UB) has a current Sloan Ratio % of -975.00%. The current Sloan Ratio % is -975.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cognetivity Neurosciences (STU:1UB), the current Sloan Ratio % is -975.00% as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1UB has been successfully added to your 
